Having trouble accessing articles? Reset your cache.

Ibrutinib: Expanded access program started

Johnson & Johnson's Janssen Research & Development LLC unit began an open-label, U.S. expanded access program to evaluate ibrutinib in

Read the full 201 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE